Is Atara Biotherapeutics, Inc. (ATRA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 117.6% / 30% | 114.0% / 30% | 4.0% / 30% | 1.64% / 5% | ✗ NOT HALAL |
| DJIM | 117.6% / 33% | 114.0% / 33% | 4.0% / 33% | 1.64% / 5% | ✗ NOT HALAL |
| MSCI | 40.2% / 33% | 39.0% / 33% | 1.4% / 33% | 1.64% / 5% | ✗ NOT HALAL |
| S&P | 117.6% / 33% | 114.0% / 33% | 4.0% / 33% | 1.64% / 5% | ✗ NOT HALAL |
| FTSE | 40.2% / 33% | 39.0% / 33% | 1.4% / 50% | 1.64% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 61.8% | |
| Operating Margin | -339.6% | |
| Net Margin | 27.1% | |
| Return on Assets (ROA) | 47.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$51M |
| Free Cash Flow | -$51M |
| Total Debt | $10M |
| Current Ratio | 0.8 |
| Total Assets | $20M |
Price & Trading
| Last Close | $4.71 |
| 50-Day MA | $5.06 |
| 200-Day MA | $10.81 |
| Avg Volume | 462K |
| Beta | -0.4 |
|
52-Week Range
$3.92
| |
About Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Atara Biotherapeutics, Inc. (ATRA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Atara Biotherapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Atara Biotherapeutics, Inc.'s debt ratio?
Atara Biotherapeutics, Inc.'s debt ratio is 117.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 40.2%.
What are Atara Biotherapeutics, Inc.'s key financial metrics?
Atara Biotherapeutics, Inc. has a market capitalization of $38M, trailing P/E ratio of 1.8, and revenue of $121M. The company maintains a gross margin of 61.8% and a net margin of 27.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.